Ancient Strains Limited (“Ancient Strains” or “ASL”) is pleased to announce that it has signed two binding agreements with strategic cannabis service providers that will greatly enhance Ancient Strains’ ability to expand its international footprint and develop unique medicinal cannabis products. One is with CannOps Consulting Services Ltd. (“CannOps”) and one is indirectly through Battalion Consol Corp. (“BATC”).

Under the terms of the agreement with CannOps (the “CannOps Agreement”), CannOps will, among other things, supply product from its genetic library, work with Ancient Strains to develop medicinal cannabis extract product lines and assist in marketing and distribution. Ancient Strains will use the genetics and strains to enhance its position in the international business of medicinal cannabis.


Pursuant to the confidential terms of the agreement with Battalion Consol Corporation (the “BATC Agreement”), Ancient Strains will purchase BATC’s minority equity interest in a licensed analytics lab located in Canada (the “LD”). The BATC Agreement will allow Ancient Strains full access to the services of the LD including import and export of product and product testing.

Both agreements are subject to final due diligence and definitive documentation, and all business dealings will be subject to regulatory approvals.

Summary of Terms

CannOps Agreement:

  • CannOps will provide seeds for cultivation and strain development;
  • CannOps will assist in offshore license acquisition, and protocols for extracts;
  • CannOps will assist in marketing and product development;
  • CannOps will receive warrants to purchase 2.5 million ASL shares exercisable at $0.40 for five years.

Battalion Consol Agreement:

  • BATC will sell its minority equity position and underlying agreement in a licensed laboratory;
  • ASL will have access to the full services of the LD including testing and services;
  • ASL will have exclusivity for product testing from India and Uruguay;
  • ASL will issue 1 million warrants exercisable at $0.40 per warrant for five years and pay $500,000 to BATC within three years to acquire the minority interest in the LD.

Samir Biswas, President of Ancient Strains, commented: “We are very pleased to have signed these agreements. The CannOps Agreement allows Ancient Strains to source high quality Canadian medicinal cannabis strains and expertise to develop our international business units, while the BATC Agreement would allow us to import and export, test and combine Canadian and Ancient Strains acquired offshore. Working closely with the experienced team at CannOps and the LD, Ancient Strains is now poised to expand its international footprint and develop unique medicinal cannabis products for what we believe is rapidly becoming a global business.”

Ancient Strains Near Term Plans:

Near-term Objectives of Ancient Strains in 2018 are:

  • Close on the current $3 million financing;
  • Continue expanding operations in Uruguay;
  • Conclude one or more international grow, extract, and sales agreements;
  • Attract additional Canadian expertise to complement the international strategy;
  • Complete a ‘go-public’ transaction and list the shares on a Canadian stock exchange.

This Press Release Is Available on The Company’s website www.AncientStrains.ca

About Ancient Strains

Ancient Strains Limited is a private Canadian federally-registered company planning to become a vertically integrated international producer of cannabis and hemp and related products, where legally allowed, as required for medical use by patients.

Ancient Strains goal is to develop an international business, using low-cost cultivation and extractions using innovative strains of cannabis genetics and Canadian expertise that will have a positive impact on people’s health worldwide.

About CannOps Consulting Services Ltd.

CannOps is an Ontario provincially-registered company founded by experts in the medicinal cannabis industry providing extensive services to the industry ranging from design and construction advice to genetics, efficacy, and standard operating procedures (SOP’s) for dosing and patient management. The dedicated staff are well—respected and have a long history of assisting both patients and companies establish appropriate medicinal protocols.

About Battalion Consol Corp.

BATC is a Canadian, federally-registered company providing merchant banking services to startup companies with a focus on the cannabis space.

Disclaimers:

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “would”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

For further information contact

Daryl Hodges, Chairman and CEO Tel (647) 271-3817
Samir Biswas, President and COO Tel: (416) 545-7214
www.AncientStrains.ca

Source: www.newsfilecorp.com

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less

Study represents the first research completed on the long-term toxicity and lifespan effects of cannabidiol in the preclinical model C. elegans

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.

Keep reading... Show less